Several experiments have confirmed that interfering peptides such as TAT-NR2B9c and TAT-GESV can produce anti-pain effects by disrupting the interaction between PSD95-nNOS and nNOS-NOS1AP, respectively, without causing dyskinesia or changing the normal nociceptive sensation (Pedersen and Gjerstad, 2008; Chen et al., 2014; Peltoniemi et al., 2016; Li S. et al., 2017). The gene discussed is NOS1; the disease is Dyskinesia.